Ebadi Atyeh; Moravvej Hamideh; Hejazi Somayeh; Younespour Shima; Ghalamkarpour Fariba
Volume 16, Issue 3 , 2013, , Pages 89-93
Abstract
Background: Despite great advances in therapeutic regimens,complete repigmentation in vitiligo is still out of reach. The aimof this assay was to study the efficacy and tolerability of repeatedneedling combined with narrowband ultraviolet B (NBUVB)therapy in the treatment of generalized, stable, refractory ...
Read More
Background: Despite great advances in therapeutic regimens,complete repigmentation in vitiligo is still out of reach. The aimof this assay was to study the efficacy and tolerability of repeatedneedling combined with narrowband ultraviolet B (NBUVB)therapy in the treatment of generalized, stable, refractory vitiligo.Method: Twenty-six patients with stable generalized intractablevitiligo were recruited in before/after clinical trial. The patientsreceived needling for selected patches weekly for 12 weeks. Allthe patients received NBUVB phototherapy three times a week.Repigmentation improvement was assessed by two blindedinvestigators at weeks 4, 8 and 12. Tolerability was assessed bya 5-point scale.Result: Twenty-two patients (16 women and 6 men) with a mean(SD) age of 34.41 (12.75) years completed the 12-week therapyperiod. In comparison with the baseline, improvement in themean percentage of repigmentation was 7.10±10.15, 12.95±20.29,and 15.57±17.38 at week 4, 8 and 12 of therapy, respectively.A significant improvement was observed in repigmentationpercentages in the three time points (p
Robati Reza; Ebadi Atyeh; Nazari Sajjad; Saffarian Zahra
Volume 14, Issue 3 , 2011, , Pages 117-118
Abstract
A 33–year-old woman was visited at the dermatological clinic of Loghman-e-Hakim Hospital with multiple hypopigmented patches on her right arm, buttocks and flanks. Her lesions developed over the past year with no regression. Lesions were resistant to multiple antifungal therapies. Clinical examination ...
Read More
A 33–year-old woman was visited at the dermatological clinic of Loghman-e-Hakim Hospital with multiple hypopigmented patches on her right arm, buttocks and flanks. Her lesions developed over the past year with no regression. Lesions were resistant to multiple antifungal therapies. Clinical examination revealed multiple circular or oval patches on the right arm, flank and sacral area. There was no erythema but fine scales were observed on the lesions (Figure1). No cutaneous sensory deficit was detected and no abnormality was found on physical examination. Also, there was no family history of similar problems. Abdominal ultrasonography and chest x-ray were normal. We performed biopsy from one of the lesions.
Malekzad Farhad; Eshghi Gholamreza; Ebadi Atyeh; Younespour Shima
Volume 13, Issue 3 , 2010, , Pages 91-95
Abstract
Background: Alopecia areata is one of the most common human autoimmune disorders and its severe types are refractory to all conventional therapies. Corticosteroids have been used in severe alopecia areata since 1950s but there is concern over complications caused by high doses of corticosteroids. Methotrexate ...
Read More
Background: Alopecia areata is one of the most common human autoimmune disorders and its severe types are refractory to all conventional therapies. Corticosteroids have been used in severe alopecia areata since 1950s but there is concern over complications caused by high doses of corticosteroids. Methotrexate has been used as an adjunctive therapy in some autoimmune disorders and has been proposed to be effective in the treatment of severe alopecia areata both as a monotherapy and in combination with corticosteroids. Methods: In this study, 120 patients of intractable alopecia areata totalis and universalis with a mean duration of 3.27 ±1.60 years were studied. We treated them with methotrexate in combination with intravenous and low dose of prednisolone for one year. Methotrexate 10 mg per week was administered in combination with three monthly methylprednisolone and oral prednisolone 15 mg per day for one year. Response to the treatment was evaluated clinically and by serial photographs. Results: Sixty four patients (57.7%) gained total hair regrowth after treatment with no significant difference between alopecia totalis and universalis. Almost half of the patients (44.75%) remained disease free until the end of the one-year follow-up. Relapse occurred in 34 patients (56.25%); of them 20% were focal relapses. Nine patients out of 120 patients (7.5%) experienced severe adverse effects of the therapy. Conclusion: Our study suggested that methotrexate could be used as a safe and well tolerated adjunctive therapy for severe alopecia areata although careful monitoring of adverse effect is necessary. Furthermore, controlled prospective clinical trials are warranted to answer many of the questions regarding methotrexate therapy for severe alopecia areata.